Investigation of Cardioprotective Potential of Remogliflozin in preventing Streptozotocin induced Diabetic Cardiomyopathy in Male Wistar Rats

Abstract

Introduction and objective - One of the cardiac problems that diabetes patients face is Diabetic Cardiomyopathy (DCM), which can lead to heart failure and an increase in morbidity and death. The two main pathogenic characteristics of diabetic hearts that contribute to the development of DCM are inflammation and oxidative stress. Because of its anti-oxidant and anti-inflammatory qualities, remogliflozin, an SGLT 2 inhibitor, has been demonstrated to lessen inflammation and oxidative stress. The purpose of this study was to look at how Remogliflozin protects diabetic hearts and assess via the corresponding changes in blood marker and histological characteristics.